| 陈小兵 冯杰 陈小菊 廖俊蕾 王涛 周辉.厄洛替尼联合多烯紫杉醇- 卡铂治疗晚期非小细胞肺癌的临床研究[J].,2014,14(21):4063-4066 |
| 厄洛替尼联合多烯紫杉醇- 卡铂治疗晚期非小细胞肺癌的临床研究 |
| Clinical Study of Erlotinib Combined with Docetaxel-carboplatin in theTreatment of Advanced Non-small Cell Lung Cancer |
| |
| DOI： |
| 中文关键词: 厄洛替尼 多烯紫杉醇 卡铂 晚期非小细胞肺癌 |
| 英文关键词: Erlotinib Docetaxel Carboplatin Advanced non-small cell lung cancer |
| 基金项目:湖南省科技厅科技计划项目资助(2012SK3249)；湖南省医药卫生科研计划课题项目资助( B2012-098) |
|
| 摘要点击次数: 791 |
| 全文下载次数: 860 |
| 中文摘要: |
| 目的：探讨厄洛替尼联合多烯紫杉醇和卡铂对晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)的临床疗效及毒副反
应。方法：选择2010 年1 月-2012年1 月我院收治的Ⅲb 或Ⅳ期非鳞状非小细胞肺癌患者共92 例。所有病例均给予多烯紫杉醇
(100mg/m3)+卡铂(AUC 5.5,浓度-时间曲线下面积5.5)治疗2 个周期，完成2 个周期治疗后，将病人随机分为对照治疗组(多烯紫
杉醇+卡铂治疗)和厄洛替尼治疗组(厄洛替尼联合多烯紫杉醇+ 卡铂治疗)，每组各46 例，厄洛替尼组给予口服厄洛替尼150
mg/dl/天剂量治疗。两组均继续治疗2 个周期，观察厄洛替尼联合多烯紫杉醇- 卡铂治疗对晚期非小细胞肺癌患者的疗效、患者
中位生存期及毒副反应。结果：两组患者治疗客观有效率对照治疗组为26.1%，厄洛替尼治疗组为45.6%，差异具有统计学意义
(P<0.05)。厄洛替尼治疗组患者中位生存期为6.9 个月。与对照治疗组相比，厄洛替尼治疗组中患者3/4 级中性粒细胞降低的发生
率显著降低，差异具有统计学意义(P < 0.05)。结论：厄洛替尼能增强多烯紫杉醇+卡铂治疗方案对晚期非小细胞肺癌的疗效，减
轻化疗的毒副反应。 |
| 英文摘要: |
| Objective:To investigate the efficacy and toxicity of erlotinib combined with docetaxel-carboplatin on advanced
non-small cell lung cancer patients.Methods:A total of 92 initially treated patients with Ⅲ b or Ⅳ non-small cell lung cancer (NSCLC)
were enrolled in this study. All the patients were treated with two cycles of carboplatin (area under the concentration-time curve 5.5) and
docetaxel 100 mg/m3. After completion of two treatment cycles, patients were randomly divided into two groups: 46 continued previous
chemotherapy (control group) until disease progression, 46 received previous chemotherapy plus erlotinib 150 mg daily until disease
progression; both for another two cycles. Then observe the curative effect, median survival and toxicity of erlotinib combined with
paclitaxel carboplatin therapy for advanced non small cell lung cancer patients.Results:Compared with control group (26.1%), the
objective response rate of erlotinib group (45.6%) was increased significantly (P<0.05). Median survival duration was 6.9 months for
erlotinib group. Compared with control group, the incidence of grade 3 and 4 neutrophile granulocyte significantly decreased in erlotinib
group (P<0.05).Conclusion:Erlotinib combined with docetaxel-carboplatin treatment could enhance the efficacy on advanced non-small
cell lung cancer and reduce toxicity of chemotherapy. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
